CN105954431A - Method for measuring substances relevant to ospemifene raw medicine through HPLC (high performance liquid chromatography) separation - Google Patents

Method for measuring substances relevant to ospemifene raw medicine through HPLC (high performance liquid chromatography) separation Download PDF

Info

Publication number
CN105954431A
CN105954431A CN201610544063.2A CN201610544063A CN105954431A CN 105954431 A CN105954431 A CN 105954431A CN 201610544063 A CN201610544063 A CN 201610544063A CN 105954431 A CN105954431 A CN 105954431A
Authority
CN
China
Prior art keywords
crude drug
related substance
ospemifene
pei meter
hplc separation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201610544063.2A
Other languages
Chinese (zh)
Other versions
CN105954431B (en
Inventor
葛德培
吴其华
刘涛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ANHUI LIANCHUANG BIOLOGICAL MEDICINE Co Ltd
Original Assignee
ANHUI LIANCHUANG BIOLOGICAL MEDICINE Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ANHUI LIANCHUANG BIOLOGICAL MEDICINE Co Ltd filed Critical ANHUI LIANCHUANG BIOLOGICAL MEDICINE Co Ltd
Priority to CN201610544063.2A priority Critical patent/CN105954431B/en
Publication of CN105954431A publication Critical patent/CN105954431A/en
Application granted granted Critical
Publication of CN105954431B publication Critical patent/CN105954431B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N2030/022Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027Liquid chromatography

Landscapes

  • Physics & Mathematics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention relates to a method for measuring substances relevant to ospemifene raw medicine through HPLC (high performance liquid chromatography) separation. The method comprises the following steps that octadecylsilane bonded silica gel is used as a filling agent; phosphoric acid is used for regulating the water pH to 2.5 to 2.5 for performing gradientelution as a flowing phase A; methyl alcohol-acetonitrile is used as a flowing phase B to perform gradientelution; the flowing speed is 0.8 to 1.2mL/min; the column temperature is 32 to 37 DEG C; an ultraviolet detector is used for detecting substances relevant to the ospemifene raw medicine. The method provided by the invention has the advantages of high speed, simplicity, convenience, high sensitivity, accuracy and reliability, and is suitable for being used for separating and measuring the substances relevant to ospemifene raw medicine. The method provided by the invention has the advantages that the detection result reaches the optimization through the overall consideration of the analytical column, the flowing phase and the gradient elution procedures and the overall influence of the flowing speed and the column temperature on the separation detection; the advantages of high speed, simplicity, convenience, high sensitivity, accuracy and reliability are realized; the method is suitable for being used for separating and measuring the substances relevant to the ospemifene raw medicine.

Description

A kind of method that HPLC separation determination Ao Pei meter Fen crude drug has related substance
Technical field
The present invention relates to the analysis determining method of a kind of Ao Pei meter Fen crude drug, be specifically related to one HPLC separation determination Ao Pei meter Fen crude drug has the method for related substance.
Background technology
Ao Pei meter Fen is a kind of estrogen-agonistic medicine with tissue selectivity effect and antagonistic.Estrogen is subject to by this medicine Body α (ER α) and β (ER β) has affinity.Its biological action is by being combined mediation with estrogen receptor.This kind combines Cause the activation (agonism) of estrogen pathway in some is organized and block other estrogen pathway (antagonism), molecule Formula is C24H23ClO2, molecular weight is 378.9, and structural formula is as follows:
In order to control the quality of Ao Pei meter Fen crude drug, need main component and impurity to be controlled, in existing skill In art, it is not suitable for analysis method quick, easy, that Accurate Analysis detection Ao Pei meter Fen crude drug has related substance.
Therefore, Ao Pei meter Fen crude drug is further improved and optimization demand with the presence of the assay method of related substance, This power that present invention is accomplished just and starting point place.
Summary of the invention
For the above-mentioned technical problem overcoming prior art to exist, the present inventor carried out substantial amounts of further investigation it After, thus provide a kind of method that HPLC separation determination Ao Pei meter Fen crude drug has related substance, have fast and convenient, sensitive Degree height, accurately and reliably advantage.
The present invention is achieved through the following technical solutions, former in particular to one HPLC separation determination Ao Pei meter Fen The method that material medicine has related substance, comprises the steps: with octadecylsilane chemically bonded silica as filler, with phosphoric acid water transfer pH extremely 2.5~3.5 is that Mobile phase B carries out gradient elution for mobile phase A, methanol-acetonitrile, and flow velocity is 0.8~1.2mL/min, and column temperature is 32~37 DEG C, UV-detector is used to have related substance to detect Ao Pei meter Fen crude drug.
Preferably, the particle diameter of described octadecylsilane chemically bonded silica is 5 μm, and column internal diameter is 4.6mm, and column length is 250mm.
Preferably, with phosphoric acid water transfer pH to 3.0 as mobile phase A.
Preferably, in described Mobile phase B, the volume ratio of methanol and acetonitrile is 30: 70.
Preferably, when gradient elution, flow velocity is 1.0mL/min, and column temperature is 35 DEG C.
Preferably, the detailed process of described gradient elution is:
Preferably, the detection wavelength of described UV-detector is 230nm.
Compared with prior art, beneficial effects of the present invention is as follows: the inventive method is by considering analytical column, flowing Phase, gradient elution program and flow velocity, the column temperature combined influence to separation detection so that testing result has reached optimization, tool Have fast and convenient, highly sensitive, advantage accurately and reliably, it is adaptable to separation determination Ao Pei meter Fen crude drug have related substance.
Accompanying drawing explanation
Fig. 1 is the liquid phase spectrogram that Ao Pei meter Fen has related substance.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is described in detail.Following example will assist in the technology of this area Personnel are further appreciated by the present invention, but limit the present invention the most in any form.It should be pointed out that, the ordinary skill to this area For personnel, without departing from the inventive concept of the premise, it is also possible to make some deformation and improvement.These broadly fall into the present invention Protection domain.
A kind of method that HPLC separation determination Ao Pei meter Fen crude drug has related substance, comprises the steps: with octadecane Base silane bonded silica gel is filler, and the particle diameter of octadecylsilane chemically bonded silica is 5 μm, and column internal diameter is 4.6mm, and column length is 250mm, with phosphoric acid water transfer pH to 3.0 as mobile phase A, volume ratio be 30: 70 methanol-acetonitrile for flowing phase, carry out gradient and wash De-, gradient elution program is shown in Table 1, and flow velocity is 1.0mL/min, and column temperature is 35 DEG C, uses UV-detector to Ao Pei meter Fen raw material The related substance that has of medicine detects, and detection wavelength is that the liquid phase spectrogram of 230nm, Ao Pei meter Fen crude drug sample is as it is shown in figure 1, Austria The peak value of Pei meter Fen crude drug sample is as shown in table 2.
Table 1 gradient elution program
Time (minute) Mobile phase A (volume %) Mobile phase B (volume %)
0 50 50
8 50 50
12 35 65
35 25 75
60 10 90
60.1 50 50
70 50 50
The peak value meter of table 2 Ao Pei meter Fen crude drug
Peak is numbered Retention time min Highly mAu Area mAu*s Area % Tailing factor Theoretical cam curve Separating degree
A 8.065 15.95 216.87 0.745 0.903 7519
B 8.679 19.75 274.91 0.945 0.949 8746 1.6
C 12.498 18.32 267.33 0.919 0.969 15898 9.9
D 14.119 16.20 210.39 0.723 0.891 27612 4.4
E 18.060 16.64 208.82 0.718 0.973 45172 11.6
F 30.086 20.11 314.15 1.079 1.017 83924 31.8
Principal agent 31.179 1681.74 27109.74 93.147 1.048 85837 2.6
G 32.075 14.30 239.60 0.823 0.933 85762 2.1
H 34.090 15.39 262.60 0.902 1.030 90517 4.5
System suitability: take Ao Pei meter Fen and impurity A, B, C, D, E, F, G, H reference substance respectively appropriate, accurate claims Fixed, put in same volumetric flask, add methanol appropriate, ultrasonic make dissolving dilution make in every 1mL containing about Ao Pei meter Fen 0.5mg, contain Each impurity is about the mixed solution of 5 μ g, and each peak separating degree should be not less than 1.5.
Concrete test operation: take this product appropriate, add methanol dissolve and quantitatively dilution make in every 1mL containing about 0.5mg molten Liquid measures 1mL as need testing solution, precision, puts in 100mL measuring bottle, with solvent dilution to scale, as contrast solution.It is right to take According to solution 20 μ L inject chromatograph of liquid, regulate detection sensitivity, make main constituent chromatographic peak peak height is full scale 10%~ 20%.Precision measures need testing solution and each 20 μ L of contrast solution again, is injected separately into chromatograph of liquid, records chromatogram.For examination If any impurity peaks in the chromatogram of product solution, single impurity peak area cannot be greater than 0.10 times of contrast solution main peak area (0.10%), the sum of each impurity peak area, cannot be greater than 1.0 times (1.0%) of the main peak area of contrast solution.(impurity C, miscellaneous Matter D, impurity E correction factor are respectively 0.74,0.80,0.80;Remaining known impurities and unknown impuritie correction factor are based on 1.0 Calculate).
Computing formula:
Total miscellaneous content=Σ other impurity contents of known impurity level+Σ
ASingle: impurity peak area AComparison: 1% comparison main peak area F: correction factor
Impurity title Relative retention time Correction factor (F)
Impurity A 0.26 0.92
Impurity B 0.28 1.06
Impurity C 0.40 0.74
Impurity D 0.45 0.80
Impurity E 0.58 0.80
Impurity F 0.96 1.00
Impurity G 1.03 0.92
Impurity H 1.09 1.04
Above the specific embodiment of the present invention is described.It is to be appreciated that the invention is not limited in above-mentioned Particular implementation, those skilled in the art can make various deformation or amendment within the scope of the claims, this not shadow Ring the flesh and blood of the present invention.

Claims (7)

1. the method having related substance with HPLC separation determination Ao Pei meter Fen crude drug, it is characterised in that comprise the steps: With octadecylsilane chemically bonded silica as filler, with phosphoric acid water transfer pH to 2.5~3.5 as mobile phase A, methanol-acetonitrile be stream Dynamic phase B carries out gradient elution, and flow velocity is 0.8~1.2mL/min, and column temperature is 32~37 DEG C, uses UV-detector to Ao Pei meter The related substance that has of fragrant crude drug detects.
2. the method having related substance with HPLC separation determination Ao Pei meter Fen crude drug as claimed in claim 1, it is characterised in that The particle diameter of described octadecylsilane chemically bonded silica is 5 μm, and column internal diameter is 4.6mm, and column length is 250mm.
3. the method having related substance with HPLC separation determination Ao Pei meter Fen crude drug as claimed in claim 1, it is characterised in that With phosphoric acid water transfer pH to 3.0 as mobile phase A.
4. the method having related substance with HPLC separation determination Ao Pei meter Fen crude drug as claimed in claim 1, it is characterised in that In described Mobile phase B, the volume ratio of methanol and acetonitrile is 30: 70.
5. the method having related substance with HPLC separation determination Ao Pei meter Fen crude drug as claimed in claim 1, it is characterised in that When gradient elution, flow velocity is 1.0mL/min, and column temperature is 35 DEG C.
6. the method having related substance with HPLC separation determination Ao Pei meter Fen crude drug as claimed in claim 1, it is characterised in that The detailed process of described gradient elution is:
7. the method having related substance with HPLC separation determination Ao Pei meter Fen crude drug as claimed in claim 1, it is characterised in that The detection wavelength of described UV-detector is 230nm.
CN201610544063.2A 2016-07-11 2016-07-11 A kind of method of the HPLC separation determination Ao Pei meter Fen bulk pharmaceutical chemicals in relation to substance Active CN105954431B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610544063.2A CN105954431B (en) 2016-07-11 2016-07-11 A kind of method of the HPLC separation determination Ao Pei meter Fen bulk pharmaceutical chemicals in relation to substance

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610544063.2A CN105954431B (en) 2016-07-11 2016-07-11 A kind of method of the HPLC separation determination Ao Pei meter Fen bulk pharmaceutical chemicals in relation to substance

Publications (2)

Publication Number Publication Date
CN105954431A true CN105954431A (en) 2016-09-21
CN105954431B CN105954431B (en) 2018-05-29

Family

ID=56899830

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610544063.2A Active CN105954431B (en) 2016-07-11 2016-07-11 A kind of method of the HPLC separation determination Ao Pei meter Fen bulk pharmaceutical chemicals in relation to substance

Country Status (1)

Country Link
CN (1) CN105954431B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114088821A (en) * 2021-08-26 2022-02-25 陕西新时代生物转化检测有限公司 Method for detecting domiphen bromide content in disinfection product

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014060640A1 (en) * 2012-10-19 2014-04-24 Fermion Oy A process for the preparation of ospemifene

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014060640A1 (en) * 2012-10-19 2014-04-24 Fermion Oy A process for the preparation of ospemifene
JP2015532309A (en) * 2012-10-19 2015-11-09 フェルミオン オサケ ユキチュア Ospemifen production method

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JOUKO UUSITALO 等: "Metabolism and metabolite profiles in vivo and in vivo of ospermifene in humans and preclinical species", 《DRUG METABOL PERS THER》 *
MITTA CHAITANYA 等: "Method development for the simultaneous estimation of ospemifine by using RP-HPLC", 《INTERNATIONAL JOURNAL OF PHARMA RESEARCH AND HEALTH SCIENCES》 *
TRACY L. TARAS 等: "Quantitative analysis of Z-2-[4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy]ethanol in human plasma using high-performance liquid chromatography", 《JOURNAL OF CHROMATOGRAPHY B》 *
郝晨洲: "奥培米芬(Ospemifene)", 《中国药物化学杂志》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114088821A (en) * 2021-08-26 2022-02-25 陕西新时代生物转化检测有限公司 Method for detecting domiphen bromide content in disinfection product

Also Published As

Publication number Publication date
CN105954431B (en) 2018-05-29

Similar Documents

Publication Publication Date Title
CN104655751B (en) A kind of detect the method for organic solvent residual in dapoxetine
CN104655766B (en) Assay method while nicotine, propylene glycol and glycerol in a kind of tobacco juice for electronic smoke
CN105092754A (en) Method for determining sulfonate genotoxic impurity by using HPLC
CN102175778A (en) Method for synchronously measuring blood drug concentrations of multiple antidepressants
CN105223282A (en) A kind of Gradient High Performance Liquid Chromatography measures the method for Abiraterone acetate related substance
CN106324128A (en) Method for measuring content of aristolochic acid compound in traditional Chinese medicine
CN107315053A (en) About the EFI fog detector liquid phase chromatography analytical method of material in a kind of lactose
CN106033079B (en) Method for detecting related substance imidazole in starting material F of dabigatran etexilate mesylate
CN105929045A (en) Method for detecting residual organic solvent in cis-atracurium besilate
CN103487545B (en) Liquid chromatography detection method for carbachol content and impurity content
CN106198819B (en) The method of residual solvent in Headspace Gas Chromatography Xi Gelieting bulk pharmaceutical chemicals
CN112710758A (en) Method for detecting residual solvent in tapentadol hydrochloride raw material medicine
CN105954431B (en) A kind of method of the HPLC separation determination Ao Pei meter Fen bulk pharmaceutical chemicals in relation to substance
CN103926350A (en) Inspection method of rehabilitation liquid formulation fingerprint and standard fingerprint
CN101458235B (en) Matrine liquid chromatography measuring method
CN101169394A (en) Cosmetic product clindamycinum high efficiency liquid chromatography detection method
CN103063794B (en) Content detecting and control method of epalrestat tablets
CN115308335A (en) Method for detecting blood concentration of aripiprazole
CN105158348A (en) Method for determining five effective components in zedoary oil by using gas chromatography
CN102121924B (en) Method for analyzing acetic acid methylprednisolone and impurities of acetic acid methylprednisolone
CN105572240A (en) Method for detecting content of pharmaceutic adjuvant carmine by using high performance liquid chromatography
CN105277633B (en) A kind of defects inspecting analysis method of norethindrone derivative and its intermediate
CN106896162A (en) A kind of HPLC methods of impurity in detection meloxicam tablet
CN102109499A (en) Method for simultaneously detecting acetone and ethyl acetate residues in drug by gas chromatography
CN111351874A (en) Method for detecting residual solvent in ibudilast bulk drug

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant